Note 5 – Supplemental disclosure for statement of cash flows

During the nine months ended April 30, 2024 and 2023, interest paid by the Company was $275 and $204, respectively.

For the nine months ended April 30, 2024 and 2023, the net reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was $306 and $5, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows.

In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs, $5,000 of escrowed proceeds were included in prepaid and other assets as of April 30, 2024 and in other assets as of July 31, 2023. In connection with the full payment of a mortgage in July 2023, the restricted cash collateral deposit of $1,000 was released during the nine months ended April 30, 2024.

During the nine months ended April 30, 2024, state taxes paid on the gain on the completed sale of certain assets used in the operation of Enzo Clinical Labs were $729. For the nine months ended April 30, 2024 and 2023, tax on capital paid by the Company was $23 and $9, respectively.

During the nine months ended April 30, 2024, the Company disbursed $474 for taxes related to net share settlement of bonuses paid in stock to a current senior executive and a former senior executive, and for taxes related to a net share settlement of a performance stock unit.